{"id":450628,"date":"2021-03-04T08:03:48","date_gmt":"2021-03-04T13:03:48","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450628"},"modified":"2021-03-04T08:03:48","modified_gmt":"2021-03-04T13:03:48","slug":"viracta-therapeutics-strengthens-company-leadership-with-new-appointments-to-the-board-of-directors-and-management-team","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-strengthens-company-leadership-with-new-appointments-to-the-board-of-directors-and-management-team\/","title":{"rendered":"Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team"},"content":{"rendered":"
\n

Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors<\/h2>\n

Cheryl A. Madsen, RAC appointed as Senior Vice President, Regulatory Affairs<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, March 4, 2021<\/span> \/PRNewswire\/ —\u00a0Viracta<\/a>\u00a0Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino<\/span> and Barry J. Simon<\/span> to the Board of Directors, the addition of Cheryl A. Madsen<\/span>, RAC as Senior Vice President, Regulatory Affairs, and the promotion of several members of the management team. <\/p>\n

“The wealth of biotech leadership and executive experience Drs. Rubino and Simon bring to the Viracta Board will be invaluable as we continue to execute on our corporate strategy,” said Roger Pomerantz<\/span>, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. “With the help of their counsel and strategic guidance, we aim to build on the momentum generated by our recent entrance into the public market and concurrent financing.”<\/p>\n

“We are very pleased to be complementing these Board additions by bringing on Cheryl Madsen<\/span> to lead our regulatory efforts,” said Ivor Royston<\/span>, M.D., President and Chief Executive Officer of Viracta. \u00a0“Cheryl has a proven record of success facilitating the regulatory processes involved in bringing oncology therapeutics to market, which will be crucial as we advance our novel all-oral combination therapy into a global registrational trial in relapsed\/refractory Epstein-Barr virus (EBV)-positive lymphoma and further expand into EBV-positive solid tumors.”\u00a0 <\/p>\n

In addition to the appointments of Ms. Madsen and Drs. Rubino and Simon, Viracta also announced the following management promotions, which are significant in the operations of Viracta as a publicly traded company:<\/p>\n